Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

M J Leandro, J C W Edwards, G Cambridge, M J Leandro, J C W Edwards, G Cambridge

Abstract

Objectives: To obtain evidence for dose response and to extend evidence of safety and efficacy for B lymphocyte depletion in rheumatoid arthritis.

Methods: Twenty two patients with rheumatoid arthritis received a total of 29 treatments with five different combinations of rituximab (RTX), cyclophosphamide (CP), and/or high dose prednisolone (PR) on an open basis as follows; cohort I: RTX 1400 mg/m(2), CP 750x2+PR; cohort II: RTX 300-700 mg/m(2), -CP+/-PR); cohort III: RTX 600-700 mg/m(2), CP 750x2+PR; cohort IV: RTX 1200 mg/m(2), CP 750x2-PR; cohort V: RTX 500 mg/m(2), CP 750x2+PR. American College of Rheumatology (ACR) criteria of improvement at six months were chosen as the primary outcome measure. Disease activity scores and total duration of improvement and of B cytopenia were also recorded.

Results: No major adverse events attributable to treatment were seen. ACR grades of improvement at six months were as follows: cohort I: ACR70x3, ACR50x2; cohort II: ACR20x1, ACR0x3; cohort III: ACR70x6, ACR50x2, ACR20x2; cohort IV: ACR70x2, ACR50x2, ACR20x1, ACR0x1; cohort V: ACR0x4.

Conclusions: B lymphocyte depletion in rheumatoid arthritis has so far proved to be safe and associated with major improvement with protocols including RTX 600 mg/m(2) or more and CP, but not with more limited protocols. These observations provide an initial basis for the design of formal trials of B cell depletion and other B cell directed treatments, including a phase II controlled trial now in progress.

Figures

Figure 1
Figure 1
Mean modified disease activity score (DAS28) for each cohort. Bars indicate minimum and maximum values.
Figure 2
Figure 2
Mean total serum immunoglobulin levels. Bars indicate minimum and maximum levels.

References

    1. J Lab Clin Med. 1999 Nov;134(5):445-50
    1. Immunology. 1998 May;94(1):56-63
    1. Semin Oncol. 1999 Oct;26(5 Suppl 14):88-96
    1. Arthritis Rheum. 2000 Mar;43(3):608-16
    1. Rheumatology (Oxford). 2001 Feb;40(2):205-11
    1. N Engl J Med. 1978 Apr 20;298(16):869-71
    1. Lancet. 1981 Oct 17;2(8251):839-42
    1. Rheumatol Int. 1983;3(4):183-6
    1. Clin Rheum Dis. 1985 Dec;11(3):551-72
    1. Arthritis Rheum. 1988 Mar;31(3):315-24
    1. J Exp Med. 1991 Feb 1;173(2):487-9
    1. Immunol Today. 1993 May;14(5):215-21
    1. Blood. 1994 Jan 15;83(2):435-45
    1. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8562-6
    1. Arthritis Rheum. 1995 Jun;38(6):727-35
    1. Annu Rev Immunol. 1995;13:127-49
    1. APMIS. 1997 Apr;105(4):257-63
    1. J Clin Oncol. 1997 Oct;15(10):3266-74
    1. Arthritis Rheum. 1998 Aug;41(8):1481-8

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する